Last reviewed · How we verify
NCT04757090
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Phase 2 trial testing 89Zr-trastuzumab in HER2-positive Solid Tumor. Withdrawn.
31 December 2023
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 31 December 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
Drugs / interventions tested
- 89Zr-trastuzumab — full drug profile →
Conditions studied
- HER2-positive Solid Tumor — all drugs for HER2-positive Solid Tumor →
- HER-2 Positive Cancer — all drugs for HER-2 Positive Cancer →
Sponsor
Washington University School of Medicine
Who can join
18 and older, any sex, with HER2-positive Solid Tumor or HER-2 Positive Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S, Li J, Yu Y, Chen Z, et al · · 2021 · cited 17× · PMID 34770887 · DOI 10.3390/molecules26216482 -
Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.
Zhou X, Dong L, Shen L. · · 2021 · cited 9× · PMID 34834087 · DOI 10.3390/molecules26226997
Verify or expand the search:
- PubMed search for NCT04757090
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 89Zr-trastuzumab
Trials testing the same drug.
- NCT06732336 — HER2-PET Imaging in HER2-low Breast Cancers · Phase 1, PHASE2 · recruiting
- NCT02286843 — Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 · NA · completed
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04757090 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 23 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04757090.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing